• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bigfoot Biomedical’s Bigfoot Unity demonstrates strong glycemic control in Type 2 diabetes

June 6, 2022 By Sean Whooley

Bigfoot Biomedical Abbott Bigfoot Unity diabetes management program
Bigfoot Biomedical’s Bigfoot Unity system. [Conceptual rendering courtesy of Bigfoot Biomedical]
Bigfoot Biomedical announced data supporting the use of its Bigfoot Unity system for improving glycemic control in those with diabetes.

Data from a real-world retrospective analysis suggests that, for those on multiple daily injections (MDI) of insulin, Bigfoot Unity has the potential to provide rapid and durable glycemic control improvements.

Milpitas, California-based Bigfoot presented the real-world data from its late-breaking abstract at the American Diabetes Association (ADA) 82nd Annual Scientific Sessions in New Orleans.

“Millions of Americans have type 2 diabetes, yet the population is largely underserved with solutions for managing insulin – and many who use a continuous glucose monitor (CGM) don’t get the full benefit because they have to calculate their insulin dose manually,” Dr. Bantwal S. Baliga, East Alabama Endocrinology and lead author of the analysis said in a news release. “We also see limitations because providers are resistant to instruct correction dosing due to fears of miscalculations and insulin stacking.”

The analysis looked at 49 people with diabetes at an average age of 60.3 years old. Bigfoot said 81.6% were type 2 and 71.7% used CGM previously but were new to smart pens and diabetes app. A minimum of 50% CGM data within the first two weeks and the third month were required to be part of the analysis.

According to Bigfoot, the study observed strong glucose control at three months of use with Bigfoot unity with the mean Glucose Management Indicator (GMI), calculated from CGM readings, coming in at 7.5% from a baseline mean HbA1c of 8.5%.

In 26 patients whose baseline HbA1c was greater than 8% (mean of 9.5%), the mean GMI at three months was 7.5%. Time spent with low glucose and very low glucose (1.5% and 0.2%, respectively) was below established medical guidelines. Additionally, engagement with the system showed promise, Bigfoot said, as more than 70% of patients followed through with a long-acting insulin dose within two hours of receiving an alert.

After six months, 95.9% of the individuals were still actively using Bigfoot Unity. Outcomes associated with the use of the platform were immediate and durable, the company said, with GMI reductions occurring within the first two weeks and continuing through the three-month analysis period.

“Our analysis demonstrates that, by using CGM data and smart technology to provide dose recommendations, Bigfoot Unity can support a therapeutic dosing regimen that can be easily adhered to – both short and long term,” Baliga said. “This is promising because when we see consistent adherence and effective insulin management, we see an improvement in overall glycemic control.”

Filed Under: Auto-injectors, Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: American Diabetes Association, Bigfoot Biomedical

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS